Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan
- PMID: 30486687
- DOI: 10.1080/13506129.2018.1531842
Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan
Abstract
Hereditary transthyretin (ATTRm) amyloidosis, formerly known as familial amyloid polyneuropathy, is a major type of hereditary systemic amyloidosis, in which the disease is caused by mutant transthyretin (TTR). Although more than 140 different point mutations have been identified in the TTR gene, ATTRm amyloidosis patients with the TTR Val30Met mutation are most frequently found worldwide. Interestingly, the onset age of the ATTR Val30Met amyloidosis is highly varied among countries and regions. The reason for these differences in onset age and penetrance remains to be elucidated. We recently performed an epidemiological study to analyze the clinical and genetic characteristics of ATTRm amyloidosis patients in Japan. Our results led us to the following questions: Why did most of the non-endemic patients with the same TTR Val30Met mutation not have a family history of the disease, a typical autosomal dominant hereditary disorder? Why does ATTR Val30Met amyloidosis alone demonstrate foci of occurrence? Why is only this type of ATTRm amyloidosis nationally and globally distributed? In this mini-review, we discuss these unanswered questions based on recent genetic epidemiological studies on ATTR Val30Met amyloidosis.
Keywords: Transthyretin; Val30Met; amyloid; hereditary transthyretin amyloidosis; late onset.
Similar articles
-
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.Orphanet J Rare Dis. 2018 Jan 17;13(1):6. doi: 10.1186/s13023-017-0726-x. Orphanet J Rare Dis. 2018. PMID: 29343286 Free PMC article. Review.
-
Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.J Neurol. 2018 Jan;265(1):134-140. doi: 10.1007/s00415-017-8640-7. Epub 2017 Nov 24. J Neurol. 2018. PMID: 29177547
-
Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.ESC Heart Fail. 2019 Feb;6(1):122-130. doi: 10.1002/ehf2.12361. Epub 2018 Oct 4. ESC Heart Fail. 2019. PMID: 30284755 Free PMC article.
-
Hereditary transthyretin-related amyloidosis.Acta Neurol Scand. 2019 Feb;139(2):92-105. doi: 10.1111/ane.13035. Epub 2018 Oct 23. Acta Neurol Scand. 2019. PMID: 30295933
-
Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy.Amyloid. 2010 Mar;17(1):32-5. doi: 10.3109/13506121003619369. Amyloid. 2010. PMID: 20132088
Cited by
-
Cardiac amyloidosis is not a single disease: a multiparametric comparison between the light chain and transthyretin forms.ESC Heart Fail. 2024 Oct;11(5):2825-2834. doi: 10.1002/ehf2.14852. Epub 2024 May 16. ESC Heart Fail. 2024. PMID: 38757395 Free PMC article.
-
Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis.Ther Clin Risk Manag. 2023 Nov 27;19:973-981. doi: 10.2147/TCRM.S361706. eCollection 2023. Ther Clin Risk Manag. 2023. PMID: 38047038 Free PMC article. Review.
-
Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.Curr Cardiovasc Risk Rep. 2021 Jun;15(6):8. doi: 10.1007/s12170-021-00670-y. Epub 2021 Apr 4. Curr Cardiovasc Risk Rep. 2021. PMID: 35280930 Free PMC article.
-
Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis.Nat Commun. 2022 Oct 27;13(1):6398. doi: 10.1038/s41467-022-33591-4. Nat Commun. 2022. PMID: 36302762 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous